BofA lowered the firm’s price target on Annexon (ANNX) to $8 from $9 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences Completes Successful Public Offering
- Annexon 25.1M share Spot Secondary priced at $2.60
- Annexon announces $75M common stock, warrants offering
- Annexon Biosciences: Promising Advancements in Late-Stage Complement Inhibitors Drive Buy Rating
- Positive Investment Outlook for Annexon Biosciences Driven by Financial Stability and Key Pipeline Developments